Hemmie Chang is a Life Sciences partner at Foley Hoag, where she chairs the Licensing & Strategic Alliances Practice Group.  Hemmie brings to the table both a strategic business perspective and legal acumen from her over two decades of experience. Focusing on complex collaboration and licensing transactions, she advises both pharmaceutical and emerging biotech companies on a wide variety of licensing matters from development to commercialization.  Most recently, Hemmie represented Zosano Pharma, Inc. in its agreement with Novo Nordisk A/S to develop a new transdermal presentation of semaglutide. She advised Good Start Genetics, Inc. in a collaboration agreement with Perkin Elmer, Inc., assisted Living Proof, Inc. in its global venture with Valiant Pharmaceutical International, Inc., and represented Metamark Genetics in its $365 million collaboration with Janssen Pharmaceuticals. She has also advised on early stage research agreements with AstraZeneca, GSK, Medtronic, Merck and Sanofi. 

Hemmie received her J.D. from Harvard Law School where she was an editor of the Harvard Law Review and her A.B. from Princeton University (Woodrow Wilson School of International and Public Affairs).